Edison issues report on BB Biotech (BION)
BB Biotech AG
WKN: A0NFN3 / Name: BB Biotech / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
59,60 €
-0,17 %
Edison issues report on BB Biotech (BION)
Edison issues report on BB Biotech (BION)
Alnylam reported that the benefits of treatment were consistent across major sub-groups of trial participants, with adverse events and geometry dash side-effects leading to study discontinuation similar for those given the drug and those given a placebo.
Neueste Beiträge
williamflores in Nasdaq Market Correction: 2 Brilliant Artificial Intelligence (AI) Stocks to Buy on the Dip, Alphabet Inc. C